Patents Assigned to SavviPharm Inc.
  • Patent number: 8415388
    Abstract: This invention is related to orotic acid compounds of taxane cytotoxic agents and in particular to the conversion of the taxanes to their orotate esters. More particularly the pharmaceutical compositions of paclitaxel orotate and docetaxel orotate provide a strategy to minimize body weight loss during primary chemotherapy and improve patient outcomes and quality of life.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: April 9, 2013
    Assignee: Savvipharm Inc.
    Inventor: Rashida A. Karmali
  • Patent number: 7470672
    Abstract: This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. There orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthrracyclines.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: December 30, 2008
    Assignee: Savvipharm Inc.
    Inventor: Rashida A. Karmali
  • Patent number: 6184227
    Abstract: Compositions and methods are described for the prevention and treatment of tissue damage caused by alcohol, therapeutically helpful drugs as well as industrial, dietary and environmental toxins, using an effective amount of salts of aminoimidazole carboxamide.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: February 6, 2001
    Assignee: SavviPharm Inc.
    Inventor: Rashida A. Karmali